| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.25 | 3e-06 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.23 | 3e-05 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.16 | 7e-05 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.13 | 9e-05 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.2 | 0.0001 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0001 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |